Skeletal consequences of thiazolidinedione therapy - PubMed (original) (raw)
Review
Skeletal consequences of thiazolidinedione therapy
A Grey. Osteoporos Int. 2008 Feb.
Abstract
Thiazolidinediones (TZDs) are agonists of the peroxisome proliferator-activated receptor gamma (PPARgamma) nuclear transcription factor. Two members of this drug class, rosiglitazone and pioglitazone, are commonly used in the management of type II diabetes mellitus, and play emerging roles in the treatment of other clinical conditions characterized by insulin resistance. Over the past decade, a consistent body of in vitro and animal studies has demonstrated that PPARgamma signaling regulates the fate of pluripotent mesenchymal cells, favoring adipogenesis over osteoblastogenesis. Treatment of rodents with TZDs decreases bone formation and bone mass. Until recently, there were no bone-related data available from studies of TZDs in humans. In the past year, however, several clinical studies have reported adverse skeletal actions of TZDs in humans. Collectively, these investigations have demonstrated that the TZDs currently in clinical use decrease bone formation and accelerate bone loss in healthy and insulin-resistant individuals, and increase the risk of fractures in the appendicular skeleton in women with type II diabetes mellitus. These observations should prompt clinicians to evaluate fracture risk in patients for whom TZD therapy is being considered, and initiate skeletal protection in at-risk individuals.
Similar articles
- Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
Grey A. Grey A. Diabetes Obes Metab. 2009 Apr;11(4):275-84. doi: 10.1111/j.1463-1326.2008.00931.x. Epub 2008 Jul 29. Diabetes Obes Metab. 2009. PMID: 18671797 Review. - Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B. Lecka-Czernik B. Curr Osteoporos Rep. 2010 Dec;8(4):178-84. doi: 10.1007/s11914-010-0027-y. Curr Osteoporos Rep. 2010. PMID: 20809203 Free PMC article. Review. - The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE. Beck GR Jr, et al. Transl Res. 2013 Mar;161(3):145-55. doi: 10.1016/j.trsl.2012.08.006. Epub 2012 Sep 27. Transl Res. 2013. PMID: 23022285 Free PMC article. Clinical Trial. - [Do thiazolidinediones harm skeletal integrity?].
Takeuchi Y. Takeuchi Y. Clin Calcium. 2008 May;18(5):650-5. Clin Calcium. 2008. PMID: 18445884 Review. Japanese. - [Thiazolidinediones and skeletal health].
Meier C, Bodmer M, Meier CR, Kraenzlin ME. Meier C, et al. Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Rev Med Suisse. 2009. PMID: 19626930 Review. French.
Cited by
- Integrative Analyses of Mitophagy-Related Genes and Mechanisms Associated with Type 2 Diabetes in Muscle Tissue.
Mao W, Zong G, Gao Y, Qu S, Cheng X. Mao W, et al. Curr Issues Mol Biol. 2024 Sep 18;46(9):10411-10429. doi: 10.3390/cimb46090619. Curr Issues Mol Biol. 2024. PMID: 39329971 Free PMC article. - Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis.
Jang EJ, Lee DH, Im SS, Yee J, Gwak HS. Jang EJ, et al. Pharmaceutics. 2023 Jun 20;15(6):1778. doi: 10.3390/pharmaceutics15061778. Pharmaceutics. 2023. PMID: 37376225 Free PMC article. Review. - Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2,4-thiazolidinediones.
Patil V, Upadhyay N, Tilekar K, Joshi H, Ramaa CS. Patil V, et al. Iran J Pharm Res. 2021 Fall;20(4):188-201. doi: 10.22037/ijpr.2021.114969.15131. Iran J Pharm Res. 2021. PMID: 35194439 Free PMC article. - Lack of Adiponectin Drives Hyperosteoclastogenesis in Lipoatrophic Mice.
Madel MB, Fu H, Pierroz DD, Schiffrin M, Winkler C, Wilson A, Pochon C, Toffoli B, Taïeb M, Jouzeau JY, Gilardi F, Ferrari S, Bonnet N, Blin-Wakkach C, Desvergne B, Moulin D. Madel MB, et al. Front Cell Dev Biol. 2021 Apr 1;9:627153. doi: 10.3389/fcell.2021.627153. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33869176 Free PMC article. - Sulfur-containing therapeutics in the treatment of Alzheimer's disease.
Zhu H, Dronamraju V, Xie W, More SS. Zhu H, et al. Med Chem Res. 2021 Feb;30(2):305-352. doi: 10.1007/s00044-020-02687-1. Epub 2021 Jan 15. Med Chem Res. 2021. PMID: 33613018 Free PMC article.
References
- Arthritis Rheum. 2001 Jan;44(1):202-11 - PubMed
- J Clin Endocrinol Metab. 2006 Sep;91(9):3404-10 - PubMed
- Mayo Clin Proc. 1979 Nov;54(11):701-7 - PubMed
- Diabetes Care. 2001 Jul;24(7):1192-7 - PubMed
- Bone. 2006 Oct;39(4):796-806 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous